Related Experiment Video

Updated: May 21, 2026

Culture of Bladder Cancer Organoids as Precision Medicine Tools
08:39

Culture of Bladder Cancer Organoids as Precision Medicine Tools

Published on: December 28, 2021

New perspectives in advanced genitourinary malignancies

Pamela Biondani1, Giuseppe Procopio, Filippo Pietrantonio

  • 1Medical Oncology Unit 1, Fondazione IRCCS Istituto Nazionale dei Tumori,Milan, Italy.

Tumori
|June 9, 2012
PubMed

Insights

Novel drugs and targeted therapies are transforming genitourinary cancer care. Understanding clinical and molecular aspects is crucial for personalized treatment and improved patient outcomes in advanced malignancies.

Area of Science:

  • Oncology
  • Genitourinary Cancer Research

Background:

  • Advanced genitourinary malignancies management is rapidly evolving.
  • Novel drugs and targeted therapies have significantly impacted treatment paradigms.

Purpose of the Study:

  • To highlight the transformation in genitourinary cancer treatment.
  • To emphasize the need for understanding clinical and molecular aspects for personalized medicine.

Main Methods:

  • Review of recent advancements in genitourinary cancer therapy.
  • Analysis of the importance of clinical and molecular profiling.

Main Results:

  • Significant progress has been made through novel drugs and targeted therapies.
  • Personalized risk-benefit assessment is essential for patient management.

Conclusions:

  • Further research and biomarker validation are expected to expand treatment options.
  • Improved outcomes in genitourinary malignancies are anticipated with continued advancements.

More Related Videos

Technical Modification of the Terminal Ureter During Total Transperitoneal Laparoscopic Nephroureterectomy for Upper Urinary Tract Urothelial Carcinoma06:39

Technical Modification of the Terminal Ureter During Total Transperitoneal Laparoscopic Nephroureterectomy for Upper Urinary Tract Urothelial Carcinoma

Published on: November 22, 2019

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies06:38

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Urinary Tract Calculi VI: Surgical Management01:25

Urinary Tract Calculi VI: Surgical Management

Procedures for Kidney StonesMedical intervention is necessary when kidney stones or renal calculi are too large to pass spontaneously (typically greater than 5 millimeters) when stones are accompanied by symptomatic infection (such as fever or pyelonephritis), when they impair kidney function, or when they cause persistent symptoms like severe pain, nausea, or urinary retention. Additionally, patients with only one kidney or those who cannot be treated with medical management also require...